Use of bismuth shield for protection of superficial radiosensitive organs in patients undergoing computed tomography: a literature review and meta-analysis

The study aimed to assess the effect of bismuth (Bi) shielding on dose reduction and image quality in computed tomography (CT) through a literature review. A search was conducted in the following databases: Web of Science, PubMed, Google Scholar, and Scopus. Studies that reported estimated dose redu...

Full description

Saved in:
Bibliographic Details
Published in:Radiological physics and technology 2019-03, Vol.12 (1), p.6-25
Main Authors: Mehnati, Parinaz, Malekzadeh, Reza, Sooteh, Mohammad Yousefi
Format: Article
Language:English
Subjects:
Backscattering
Beams (radiation)
Bismuth
Breast
Computation
Computed tomography
Image quality
Imaging
Literature reviews
Medical and Radiation Physics
Medical imaging
Medicine
Medicine & Public Health
Meta-analysis
Nuclear Medicine
Organs
Patients
Radiation dosage
Radiation shielding
Radiology
Radiotherapy
Reduction
Regression analysis
Scientific papers
Search engines
Thyroid gland
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study aimed to assess the effect of bismuth (Bi) shielding on dose reduction and image quality in computed tomography (CT) through a literature review. A search was conducted in the following databases: Web of Science, PubMed, Google Scholar, and Scopus. Studies that reported estimated dose reduction with bismuth shielding during imaging of the eye, thyroid, and breast were included, and a meta-regression analysis was used to examine the influence of the CT scanner type on the dose reduction. The studies included a total of 237 patients and 34 pediatric and adult anthropomorphic phantoms for whom the radiation dose was reported. Bismuth shielding was recommended in 88.89% of the studies based on the maintenance of appropriate image quality under shielding. Noise associated with Bi shielding was 7.5%, 263%, and 23.5% for the eye, thyroid, and breast, respectively. The fixed-effects pooled estimate of dose reduction was 34% (95% CI: 13–55; p  
ISSN:1865-0333
1865-0341
DOI:10.1007/s12194-019-00500-2